People · Operator
Named in public records as an officer, director or promoter · active 2017–2026 · Biotech / Pharma, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CollPlant Biotechnologies Ltd | — | Biotech / Pharma | Series A | $17.8M | $9.9M | 2026 |
| Nephros Inc | — | Other Health Care | Seed | $12.0M | $19.2M | 2017 |
| RVL Pharmaceuticals plc | — | Pharmaceuticals | Series A | $5.0M | $38.1M | 2023 |
Alisa Lask at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alisa Lask on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Mieyal | 1 | 5 |
| Paul A. Mieyal | 1 | 4 |
| Hugh Evans | 1 | 4 |
| Roger Pomerantz | 1 | 4 |
| Daron Evans | 1 | 3 |
| BRIAN MARKISON | 1 | 3 |
| Moshe Pinto | 1 | 2 |
| Arthur Amron | 1 | 2 |
| Elan Penn | 1 | 2 |
| James S. Scibetta | 1 | 2 |
| Andrew Astor | 1 | 2 |
| Matthew Rosenberg | 1 | 2 |
| Joseph Zarzewsky | 1 | 2 |
| Adi Goldin | 1 | 2 |
| Abraham Havron | 1 | 2 |
| Gerald J. Kochanski | 1 | 1 |
| Malcolm Persen | 1 | 1 |
| Dr. Paul A. Mieyal | 1 | 1 |
| Bowman Bagley | 1 | 1 |
| Lawrence Centella | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.